Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?

Trial Profile

Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?

Not yet recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Losartan (Primary) ; Valsartan (Primary)
  • Indications Hypertension
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 26 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top